Zhejiang Starry Pharmaceutical Co.,Ltd.
SSE:603520.SS
10.42 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,350.225 | 2,195.986 | 2,131.24 | 1,999.917 | 1,367.087 | 1,308.842 | 890.471 | 710.939 | 672.945 | 695.66 | 658.483 | 685.905 | 574.711 | 506.582 |
| Cost of Revenue
| 1,893.499 | 1,662.659 | 1,618.788 | 1,251.941 | 765.728 | 749.661 | 530.064 | 444.291 | 416.241 | 437.172 | 451.016 | 503.519 | 432.631 | 345.203 |
| Gross Profit
| 456.725 | 533.327 | 512.452 | 747.976 | 601.359 | 559.181 | 360.406 | 266.648 | 256.704 | 258.488 | 207.466 | 182.386 | 142.08 | 161.379 |
| Gross Profit Ratio
| 0.194 | 0.243 | 0.24 | 0.374 | 0.44 | 0.427 | 0.405 | 0.375 | 0.381 | 0.372 | 0.315 | 0.266 | 0.247 | 0.319 |
| Reseach & Development Expenses
| 140.672 | 134.564 | 132.609 | 124.581 | 87.843 | 77.775 | 66.131 | 53.128 | 49.062 | 40.392 | 31.518 | 31.365 | 27.862 | 0 |
| General & Administrative Expenses
| 46.787 | 51.242 | 68.801 | 52.821 | 70.354 | 49.705 | 44.53 | 27.301 | 23.589 | 18.24 | 17.921 | 13.072 | 14.872 | 58.512 |
| Selling & Marketing Expenses
| 118.624 | 91.279 | 70.814 | 22.598 | 11.538 | 13.141 | 11.552 | 9.71 | 16.345 | 11.563 | 9.883 | 9.993 | 11.32 | 9.331 |
| SG&A
| 165.411 | 142.521 | 139.615 | 75.419 | 81.892 | 62.846 | 56.083 | 37.011 | 39.934 | 29.803 | 27.804 | 23.065 | 26.193 | 67.843 |
| Other Expenses
| 204.155 | 207.051 | 68.332 | 67.844 | 66.335 | 72.416 | -8.112 | -3.38 | 5.519 | -0.308 | 7.511 | 4.581 | 5.12 | 0.959 |
| Operating Expenses
| 510.239 | 484.136 | 340.556 | 267.844 | 236.069 | 213.036 | 175.269 | 137.319 | 141.128 | 124.941 | 99.155 | 84.542 | 78.663 | 69.873 |
| Operating Income
| -53.513 | 151.567 | 152.429 | 399.765 | 401.06 | 330.974 | 126.829 | 106.873 | 93.417 | 93.68 | 75.017 | 70.698 | 37.287 | 77.239 |
| Operating Income Ratio
| -0.023 | 0.069 | 0.072 | 0.2 | 0.293 | 0.253 | 0.142 | 0.15 | 0.139 | 0.135 | 0.114 | 0.103 | 0.065 | 0.152 |
| Total Other Income Expenses Net
| -3.658 | -96.232 | -217.833 | -45.726 | 9.763 | -109.075 | -55.921 | -3.38 | -18.213 | -36.773 | -27.975 | -23.667 | -22.455 | 0.173 |
| Income Before Tax
| -57.171 | 55.334 | -65.405 | 395.392 | 303.699 | 221.898 | 118.717 | 103.492 | 97.449 | 93.372 | 79.848 | 73.806 | 41.715 | 77.412 |
| Income Before Tax Ratio
| -0.024 | 0.025 | -0.031 | 0.198 | 0.222 | 0.17 | 0.133 | 0.146 | 0.145 | 0.134 | 0.121 | 0.108 | 0.073 | 0.153 |
| Income Tax Expense
| -8.068 | 0.799 | 6.521 | 65.624 | 50.101 | 38.977 | 23.178 | 22.067 | 21.543 | 19.905 | 12.822 | 11.006 | 6.716 | 10.081 |
| Net Income
| -49.099 | 44.232 | -71.926 | 323.755 | 238.729 | 170.332 | 93.676 | 83.117 | 76.122 | 68.944 | 67.704 | 63.658 | 35.785 | 67.567 |
| Net Income Ratio
| -0.021 | 0.02 | -0.034 | 0.162 | 0.175 | 0.13 | 0.105 | 0.117 | 0.113 | 0.099 | 0.103 | 0.093 | 0.062 | 0.133 |
| EPS
| -0.12 | 0.13 | -0.21 | 0.95 | 0.71 | 0.52 | 0.29 | 0.25 | 0.25 | 0.28 | 0.27 | 0.26 | 0.15 | 0.27 |
| EPS Diluted
| -0.12 | 0.13 | -0.21 | 0.95 | 0.71 | 0.52 | 0.29 | 0.25 | 0.25 | 0.28 | 0.27 | 0.26 | 0.15 | 0.27 |
| EBITDA
| 261.159 | 327.918 | 312.871 | 628.702 | 524.488 | 417.01 | 270.668 | 211.99 | 189.845 | 188.006 | 162.788 | 144.943 | 102.867 | 115.621 |
| EBITDA Ratio
| 0.111 | 0.149 | 0.147 | 0.314 | 0.384 | 0.319 | 0.304 | 0.298 | 0.282 | 0.27 | 0.247 | 0.211 | 0.179 | 0.228 |